Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$1.18
+2.2%
$1.27
$0.85
$4.40
$37.97M0.2131,403 shs2,252 shs
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$4.04
-0.1%
$4.22
$1.00
$5.87
$35.79M0.71145,217 shs11,274 shs
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$0.98
+3.1%
$0.93
$0.64
$1.58
$39.33M-0.835,532 shs16,172 shs
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
$0.01
-14.4%
$0.01
$0.00
$0.03
$9.62M0.35155,331 shs1.04 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00%+1.80%-8.17%+7.27%-58.89%
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
0.00%+2.67%-14.69%+46.20%+120.81%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
0.00%+4.84%-2.01%+40.49%-30.60%
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
0.00%-3.06%-20.17%-13.64%-52.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
1.5335 of 5 stars
0.05.00.00.01.83.30.0
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.6344 of 5 stars
3.35.00.00.00.01.70.0
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
2.5598 of 5 stars
3.55.00.00.00.00.01.3
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.50
Moderate Buy$12.00197.40% Upside
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$6.25541.03% Upside
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A$0.84 per shareN/A
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$1.04 per shareN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M2.63N/AN/A$3.23 per share0.30
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$19.79MN/A0.00N/AN/A-213.59%-65.60%8/18/2025 (Estimated)
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-$12.54MN/A0.00N/AN/AN/AN/A8/4/2025 (Estimated)
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A

Latest CUBT, AKTX, BRNS, and ATHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.34-$0.49-$0.15-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/A
0.16
0.16
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/A
3.84
N/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
9.18
9.18
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
932.18 million19.92 millionNot Optionable
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
108.87 million5.43 millionNot Optionable
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million37.11 millionN/A
Curative Biotechnology, Inc. stock logo
CUBT
Curative Biotechnology
N/A1.01 billionN/ANot Optionable

Recent News About These Companies

Curative Biotechnology, Inc. (CUBT) - Yahoo Finance
SFRX Seafarer Exploration Corp.
3 Best Biotech Stocks to Add to Your Portfolio
Sacramento Biotech News
Curative Biotechnology, Inc. (CUBT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.18 +0.03 (+2.16%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$4.04 -0.01 (-0.12%)
Closing price 07/3/2025 01:19 PM Eastern
Extended Trading
$4.02 -0.02 (-0.47%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$0.98 +0.03 (+3.07%)
Closing price 07/3/2025 01:46 PM Eastern
Extended Trading
$0.98 0.00 (0.00%)
As of 07/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Curative Biotechnology stock logo

Curative Biotechnology OTCMKTS:CUBT

$0.0095 0.00 (-14.41%)
As of 07/3/2025 12:52 PM Eastern

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.